Harbour BioMed Reports Phase I Success for HBM9378 Antibody
Cambridge, Massachusetts, USA / Rotterdam, Netherlands / Shanghai, China | March 22, 2026 Harbour BioMed has announced the online...
Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
Cambridge, Massachusetts, USA / Rotterdam, Netherlands / Shanghai, China | March 22, 2026 Harbour BioMed has announced the online...
LEIDEN, Netherlands, Feb. 1, 2026 — Pharming Group announced that the U.S. Food and Drug Administration (FDA) has issued...
SAN MATEO, Calif., Dec. 18, 2025 — Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company focused on metabolic and fibrotic...
